The MD Anderson prostate cancer PDX series (MDA PCa PDX) also captures the molecular landscape of AR alterations, ERG fusions, and PTEN loss, as well as rare or unappreciated mutations, such as a focal deletion of the SPOPL gene, providing unique models to study the significance of specific genomic alterations in prostate tumors [65]. This evidence concerns the gene AR and prostate cancer.